Biosimilars in Retina Care: What Your Practice Needs to Know in 2026

The biosimilar wave has arrived in retina care — and it's reshaping the economics of how community practices purchase, dispense, and manage their most critical therapeutics. For independent retina practices, understanding this shift isn't optional. It's essential to protecting your bottom line.

Over the past two years, biosimilar approvals for key retina biologics have accelerated dramatically. For practices that have historically relied on originator products, this creates both an opportunity and a decision point. The cost savings biosimilars offer can be significant — but navigating formulary decisions, patient conversations, and contract structures requires careful planning.

Here's what independent retina practices should be thinking about right now:

1. Understand your contract landscape. Not all GPO contracts are created equal. Some agreements lock you into originator products without accounting for biosimilar alternatives. Make sure your GPO is actively negotiating contracts that give you flexibility as the biosimilar market matures.

2. Educate your clinical team. Biosimilar adoption starts with physician and staff confidence. Investing in targeted clinical education — understanding efficacy data, interchangeability designations, and patient communication strategies — is critical to smooth transitions.

3. Track your utilization data. Practices that have real-time visibility into their drug utilization are better positioned to make the switch at the right time and capture the financial benefit.

4. Stay ahead of payer policy. Payer coverage decisions around biosimilars are still evolving. Staying current on prior authorization requirements and reimbursement policy changes is essential to avoiding revenue disruption.

The biosimilar era is here. Retina Alliance is helping members stay informed, stay flexible, and stay ahead.